BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/7/2021 5:49:13 PM | Browse: 169 | Download: 346
Publication Name World Journal of Clinical Cases
Manuscript ID 60185
Country/Territory China
Category Immunology
Manuscript Type Case Report
Article Title Human menstrual-blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of literature
Manuscript Source Unsolicited Manuscript
All Author List Juan Lu, Zhong-Yang Xie, Dan-Hua Zhu and Lan-Juan Li
Funding Agency and Grant Number
Corresponding Author Lan-Juan Li, FAASLD, Attending Doctor, Chairman, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79 Qing-chun Road, Hangzhou 310003, Zhejiang, China. ljli@zju.edu.cn
Key Words COVID-19; Human menstrual-blood-derived stem cells; Immunoregulatory therapy; Inflammatory response; Cytokine storm; Case report
Core Tip The coronavirus disease 2019 (COVID-19) is the word that certainly isn’t forgotten by everybody who lives in the first half of the twenty-first century.It has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, there is still no current effective guidance for the clinical management of COVID-19. Mesenchymal stem cells are widely used to treat tissue and organ injuries with effective immunomodulatory and repair capacities, which makes them ideal for allogenic adoptive transfer therapy. In this study, we describe the first confirmed case of COVID-19 in Hangzhou, China to explore the role of human menstrual blood-derived stem cells (MenSCs) in the treatment of COVID-19. Moreover, we review the immunomodulation effect including non-specific and specific immune functions of MenSCs for the therapy of COVID-19, which can be helpful to find a promisingly therapeutic approach for this disease.
Citation Lu J, Xie ZY, Zhu DH, Li LJ. Human menstrual-blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of literature. World J Clin Cases 2021; 9(7): 1705-1713
Received
2020-10-23 12:19
Peer-Review Started
2020-10-23 12:19
To Make the First Decision
Return for Revision
2020-11-20 07:41
Revised
2020-12-24 16:40
Second Decision
2021-01-07 12:05
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2021-01-07 17:49
Articles in Press
2021-01-07 17:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
2021-01-21 00:07
Typeset the Manuscript
2021-02-24 06:15
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com